JG
PBE icon

Jefferies Group’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Jefferies Group’s Portfolio PBE Stock Details PBE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-28
Closed -$1K – 2302
2013
Q4 		$1K Buy
+28
New +$1K ﹤0.01% 1860

Other funds holding PBE

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
U
UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
TAM
Trillium Asset Management Boston, Massachusetts $3.01B AUM 19.96% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
NCM
Niemann Capital Management Stateline, Nevada $788K AUM 23.27% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Jefferies Group's PBE Position: Q1 2014 in Review

Jefferies Group sold out of Invesco Biotechnology & Genome ETF (PBE) in Q1 2014, closing a stake of 28 shares — an estimated $1K sold.

Jefferies Group first reported a position in PBE in Q4 2013 and held it in 1 quarter. The position peaked at $1K in Q4 2013. 73 funds tracked by Wall St. Rank hold PBE as of Q1 2014.

  • Jefferies Group reported no remaining Invesco Biotechnology & Genome ETF position as of Q1 2014 after selling out during the quarter.
  • Jefferies Group sold 28 Invesco Biotechnology & Genome ETF shares in Q1 2014, an estimated $1K.
  • Jefferies Group first reported a position in Invesco Biotechnology & Genome ETF in Q4 2013 and held it in 1 quarter.
  • Jefferies Group's Invesco Biotechnology & Genome ETF position peaked at $1K in Q4 2013.
  • 73 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q1 2014.

Based on Jefferies Group's 13F filing for Q1 2014, filed 16 May 2014.